Meeting
2020 Genitourinary Cancers Symposium
Quality of life outcomes from a phase III trial exploring optimal sequencing of androgen deprivation therapy with external beam radiotherapy in localized prostate cancer.
Authors
Soumyajit Roy
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
Soumyajit Roy , Scott Grimes , Libni Eapen , Choan E , Kyle Malone , Julia Craig , Scott Carlyle Morgan , Shawn Malone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Clinical Trial Registration Number
DC-990-0082
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 315)
Abstract #
315
Poster Bd #
L21
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).
First Author: Scott Williams
Poster
2017 ASCO Annual Meeting
Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).
First Author: Scott Williams
Poster
2016 ASCO Annual Meeting
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).
First Author: Scott G. Williams
Poster
2015 ASCO Annual Meeting
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303).
First Author: Scott G. Williams